The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

This leaflet answers some common questions about Carbamazepine Sandoz. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Quetiapine is an antipsychotic medication that people who live with ... The companies whose products are in shortage — Arrotex, Sandoz and Accord Healthcare — have blamed manufacturing ...

PYZCHIVA becomes Samsung Bioepis’ fifth biosimilar and third immunology biosimilar to be launched in the US Commercialized by Sandoz, PYZCHIVA offers three different strengths Samsung Bioepis Co ...

Most generics and biosimilars in the US contain ingredients made elsewhere or are produced entirely abroad, which will hit consumers immediately, Richard Saynor, the chief executive officer of Sandoz ...